dc.contributor.author | Mojarrad, JS | |
dc.contributor.author | Vo, D | |
dc.contributor.author | Vel?zquez, C | |
dc.contributor.author | Knaus, EE | |
dc.date.accessioned | 2018-08-26T08:51:27Z | |
dc.date.available | 2018-08-26T08:51:27Z | |
dc.date.issued | 2005 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/53400 | |
dc.description.abstract | A group of alkyl 7,7-dihalo-3-methyl-5-(2- or 3-nitrophenyl)-2- azabicyclo[4.1.0]hept-3-ene-4-carboxylates were prepared by reaction of dihalocarbenes (:CX2, X = Br, Cl) with alkyl 2-methyl-4-(2- or 3-nitrophenyl)-1,4-dihydropyridine-3-carboxylates. In vitro calcium channel antagonist activities were determined using a guinea pig ileum longitudinal smooth muscle assay. The title compounds exhibited weaker CC antagonist activity (10-5 to 10-7 M range) than the reference drug nifedipine (1.4 أ— 10-8 M). Structure-activity relationships showed that the position (ortho or meta) of the nitro-substituent on the C-5 phenyl ring, the size (van der Waal's radius for Br and Cl are 1.95 and 1.80 ?, respectively) and/or electronegativity (Cl > Br) of the C-7 geminal halogen atoms do not appear to have a significant effect on CC antagonist activity. In contrast, the effect of the alkyl ester substituent was more pronounced where compounds having a Me or Et alkyl ester group showed superior potency (IC 50 in the 10-7 M range) relative to the reference drug nifedipine (IC50 = 1.40 أ— 10-8 M). Replacement of a 2-methyl-3-methoxycarbonylvinyl moiety present in nifedipine by a bioisosteric geminal-dihalocyclopropyl moiety provided a novel class of calcium channel antagonists that do not exhibit any inotropic effect on guinea pig atria. é 2005 Elsevier Ltd. All rights reserved. | |
dc.language.iso | English | |
dc.relation.ispartof | Bioorganic and Medicinal Chemistry | |
dc.subject | calcium channel | |
dc.subject | carbenoid | |
dc.subject | carboxylic acid derivative | |
dc.subject | ethyl 7,7 dibromo 3 methyl 5 (2 nitrophenyl) 2 azabicyclo[4.1.0]hept 3 ene 4 carboxylate | |
dc.subject | isobutyl 7,7 dibromo 3 methyl 5 (2 nitrophenyl) 2 azabicyclo[4.1.0]hept 3 ene 4 carboxylate | |
dc.subject | isopropyl 7,7 dibromo 3 methyl 5 (2 nitrophenyl) 2 azabicyclo[4.1.0]hept 3 ene 4 carboxylate | |
dc.subject | methyl 7,7 dibromo 3 methyl 5 (2 nitrophenyl) 2 azabicyclo[4.1.0]hept 3 ene 4 carboxylate | |
dc.subject | methyl 7,7 dibromo 3 methyl 5 (3 nitrophenyl) 2 azabicyclo[4.1.0]hept 3 ene 4 carboxylate | |
dc.subject | methyl 7,7 dichloro 3 methyl 5 (2 nitrophenyl) 2 azabicyclo[4.1.0]hept 3 ene 4 carboxylate | |
dc.subject | methyl 7,7 dichloro 3 methyl 5 (3 nitrophenyl) 2 azabicyclo[4.1.0]hept 3 ene 4 carboxylate | |
dc.subject | nifedipine | |
dc.subject | tert butyl 7,7 dibromo 3 methyl 5 (2 nitrophenyl) 2 azabicyclo[4.1.0]hept 3 ene 4 carboxylate | |
dc.subject | unclassified drug | |
dc.subject | animal tissue | |
dc.subject | article | |
dc.subject | controlled study | |
dc.subject | drug activity | |
dc.subject | drug design | |
dc.subject | drug effect | |
dc.subject | drug potency | |
dc.subject | drug structure | |
dc.subject | drug synthesis | |
dc.subject | guinea pig | |
dc.subject | IC 50 | |
dc.subject | ileum | |
dc.subject | in vitro study | |
dc.subject | inotropism | |
dc.subject | nonhuman | |
dc.subject | reaction analysis | |
dc.subject | smooth muscle | |
dc.subject | structure activity relation | |
dc.subject | Animals | |
dc.subject | Calcium Channel Blockers | |
dc.subject | Carboxylic Acids | |
dc.subject | Dose-Response Relationship, Drug | |
dc.subject | Drug Design | |
dc.subject | Esters | |
dc.subject | Guinea Pigs | |
dc.subject | Heart Atria | |
dc.subject | Ileum | |
dc.subject | Inhibitory Concentration 50 | |
dc.subject | Muscle Contraction | |
dc.subject | Muscle, Smooth | |
dc.subject | Structure-Activity Relationship | |
dc.subject | Cavia porcellus | |
dc.subject | Sus scrofa | |
dc.title | Design and synthesis of alkyl 7,7-dihalo-3-methyl-5-(nitrophenyl)-2- azabicyclo[4.1.0]hept-3-ene-4-carboxylates with calcium channel antagonist activity | |
dc.type | Article | |
dc.citation.volume | 13 | |
dc.citation.issue | 12 | |
dc.citation.spage | 4085 | |
dc.citation.epage | 4091 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.1016/j.bmc.2005.03.047 | |